Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction

Albert L. Waldo, A. John Camm, Hans DeRuyter, Peter L. Friedman, Daniel J. MacNeil, John F. Pauls, Bertram Pitt, Craig M. Pratt, Peter J. Schwartz, Enrico P. Veltri

Research output: Contribution to journalArticle

Abstract

Background. Left ventricular dysfunction after myocardial infarction is associated with an increased risk of death. Other studies have suggested that a potassium-channel blocker might reduce this risk with minimal adverse effects. We investigated whether d-sotalol, a pure potassium-channel blocker with no clinically significant beta-blocking activity, could reduce all-cause mortality in these high-risk patients. Methods. Patients with a left ventricular ejection fraction of 40% or less and either a recent (6-42 days) myocardial infarction or symptomatic heart failure with a remote (> 42 days) myocardial infarction were randomly assigned d-sotalol (100 mg increased to 200 mg twice daily, if tolerated) or matching placebo twice daily. Findings. After 3121 of the planned 6400 patients had been recruited, the trial was stopped. Among 1549 patients assigned d-sotalol, there were 78 deaths (5.0%) compared with 48 deaths (3.1%) among the 1572 patients assigned placebo (relative risk 1.65 [95% Cl 1.15-2.36], p = 0.006). Presumed arrhythmic deaths (relative risk 1.77 [1.15-2.74], p = 0.008) accounted for the increased mortality. The effect was greater in patients with a left ventricular ejection fraction of 31-40% than in those with lower (≤ 30%) ejection fractions (relative risk 4.0 vs 1.2, p = 0.007). Interpretation. Among the 1549 patients evaluated, administration of d-sotalol was associated with increased mortality, which was presumed primarily to be due to arrhythmias. The prophylactic use of a specific potassium-channel blocker does not reduce mortality, and may be associated with increased mortality in high-risk patients after myocardial infarction.

Original languageEnglish
Pages (from-to)7-12
Number of pages6
JournalLancet
Volume348
Issue number9019
DOIs
Publication statusPublished - Jul 6 1996

Fingerprint

Sotalol
Left Ventricular Dysfunction
Myocardial Infarction
Mortality
Potassium Channel Blockers
Stroke Volume
Placebos
Cardiac Arrhythmias
Heart Failure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Waldo, A. L., Camm, A. J., DeRuyter, H., Friedman, P. L., MacNeil, D. J., Pauls, J. F., ... Veltri, E. P. (1996). Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet, 348(9019), 7-12. https://doi.org/10.1016/S0140-6736(96)02149-6

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. / Waldo, Albert L.; Camm, A. John; DeRuyter, Hans; Friedman, Peter L.; MacNeil, Daniel J.; Pauls, John F.; Pitt, Bertram; Pratt, Craig M.; Schwartz, Peter J.; Veltri, Enrico P.

In: Lancet, Vol. 348, No. 9019, 06.07.1996, p. 7-12.

Research output: Contribution to journalArticle

Waldo, AL, Camm, AJ, DeRuyter, H, Friedman, PL, MacNeil, DJ, Pauls, JF, Pitt, B, Pratt, CM, Schwartz, PJ & Veltri, EP 1996, 'Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction', Lancet, vol. 348, no. 9019, pp. 7-12. https://doi.org/10.1016/S0140-6736(96)02149-6
Waldo, Albert L. ; Camm, A. John ; DeRuyter, Hans ; Friedman, Peter L. ; MacNeil, Daniel J. ; Pauls, John F. ; Pitt, Bertram ; Pratt, Craig M. ; Schwartz, Peter J. ; Veltri, Enrico P. / Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. In: Lancet. 1996 ; Vol. 348, No. 9019. pp. 7-12.
@article{d8dd3c51e7974f0b9ffd41127bcd887b,
title = "Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction",
abstract = "Background. Left ventricular dysfunction after myocardial infarction is associated with an increased risk of death. Other studies have suggested that a potassium-channel blocker might reduce this risk with minimal adverse effects. We investigated whether d-sotalol, a pure potassium-channel blocker with no clinically significant beta-blocking activity, could reduce all-cause mortality in these high-risk patients. Methods. Patients with a left ventricular ejection fraction of 40{\%} or less and either a recent (6-42 days) myocardial infarction or symptomatic heart failure with a remote (> 42 days) myocardial infarction were randomly assigned d-sotalol (100 mg increased to 200 mg twice daily, if tolerated) or matching placebo twice daily. Findings. After 3121 of the planned 6400 patients had been recruited, the trial was stopped. Among 1549 patients assigned d-sotalol, there were 78 deaths (5.0{\%}) compared with 48 deaths (3.1{\%}) among the 1572 patients assigned placebo (relative risk 1.65 [95{\%} Cl 1.15-2.36], p = 0.006). Presumed arrhythmic deaths (relative risk 1.77 [1.15-2.74], p = 0.008) accounted for the increased mortality. The effect was greater in patients with a left ventricular ejection fraction of 31-40{\%} than in those with lower (≤ 30{\%}) ejection fractions (relative risk 4.0 vs 1.2, p = 0.007). Interpretation. Among the 1549 patients evaluated, administration of d-sotalol was associated with increased mortality, which was presumed primarily to be due to arrhythmias. The prophylactic use of a specific potassium-channel blocker does not reduce mortality, and may be associated with increased mortality in high-risk patients after myocardial infarction.",
author = "Waldo, {Albert L.} and Camm, {A. John} and Hans DeRuyter and Friedman, {Peter L.} and MacNeil, {Daniel J.} and Pauls, {John F.} and Bertram Pitt and Pratt, {Craig M.} and Schwartz, {Peter J.} and Veltri, {Enrico P.}",
year = "1996",
month = "7",
day = "6",
doi = "10.1016/S0140-6736(96)02149-6",
language = "English",
volume = "348",
pages = "7--12",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9019",

}

TY - JOUR

T1 - Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction

AU - Waldo, Albert L.

AU - Camm, A. John

AU - DeRuyter, Hans

AU - Friedman, Peter L.

AU - MacNeil, Daniel J.

AU - Pauls, John F.

AU - Pitt, Bertram

AU - Pratt, Craig M.

AU - Schwartz, Peter J.

AU - Veltri, Enrico P.

PY - 1996/7/6

Y1 - 1996/7/6

N2 - Background. Left ventricular dysfunction after myocardial infarction is associated with an increased risk of death. Other studies have suggested that a potassium-channel blocker might reduce this risk with minimal adverse effects. We investigated whether d-sotalol, a pure potassium-channel blocker with no clinically significant beta-blocking activity, could reduce all-cause mortality in these high-risk patients. Methods. Patients with a left ventricular ejection fraction of 40% or less and either a recent (6-42 days) myocardial infarction or symptomatic heart failure with a remote (> 42 days) myocardial infarction were randomly assigned d-sotalol (100 mg increased to 200 mg twice daily, if tolerated) or matching placebo twice daily. Findings. After 3121 of the planned 6400 patients had been recruited, the trial was stopped. Among 1549 patients assigned d-sotalol, there were 78 deaths (5.0%) compared with 48 deaths (3.1%) among the 1572 patients assigned placebo (relative risk 1.65 [95% Cl 1.15-2.36], p = 0.006). Presumed arrhythmic deaths (relative risk 1.77 [1.15-2.74], p = 0.008) accounted for the increased mortality. The effect was greater in patients with a left ventricular ejection fraction of 31-40% than in those with lower (≤ 30%) ejection fractions (relative risk 4.0 vs 1.2, p = 0.007). Interpretation. Among the 1549 patients evaluated, administration of d-sotalol was associated with increased mortality, which was presumed primarily to be due to arrhythmias. The prophylactic use of a specific potassium-channel blocker does not reduce mortality, and may be associated with increased mortality in high-risk patients after myocardial infarction.

AB - Background. Left ventricular dysfunction after myocardial infarction is associated with an increased risk of death. Other studies have suggested that a potassium-channel blocker might reduce this risk with minimal adverse effects. We investigated whether d-sotalol, a pure potassium-channel blocker with no clinically significant beta-blocking activity, could reduce all-cause mortality in these high-risk patients. Methods. Patients with a left ventricular ejection fraction of 40% or less and either a recent (6-42 days) myocardial infarction or symptomatic heart failure with a remote (> 42 days) myocardial infarction were randomly assigned d-sotalol (100 mg increased to 200 mg twice daily, if tolerated) or matching placebo twice daily. Findings. After 3121 of the planned 6400 patients had been recruited, the trial was stopped. Among 1549 patients assigned d-sotalol, there were 78 deaths (5.0%) compared with 48 deaths (3.1%) among the 1572 patients assigned placebo (relative risk 1.65 [95% Cl 1.15-2.36], p = 0.006). Presumed arrhythmic deaths (relative risk 1.77 [1.15-2.74], p = 0.008) accounted for the increased mortality. The effect was greater in patients with a left ventricular ejection fraction of 31-40% than in those with lower (≤ 30%) ejection fractions (relative risk 4.0 vs 1.2, p = 0.007). Interpretation. Among the 1549 patients evaluated, administration of d-sotalol was associated with increased mortality, which was presumed primarily to be due to arrhythmias. The prophylactic use of a specific potassium-channel blocker does not reduce mortality, and may be associated with increased mortality in high-risk patients after myocardial infarction.

UR - http://www.scopus.com/inward/record.url?scp=8944234858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8944234858&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(96)02149-6

DO - 10.1016/S0140-6736(96)02149-6

M3 - Article

C2 - 8691967

AN - SCOPUS:8944234858

VL - 348

SP - 7

EP - 12

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9019

ER -